BR9910305A - Vaccine - Google Patents

Vaccine

Info

Publication number
BR9910305A
BR9910305A BR9910305A BR9910305A BR9910305A BR 9910305 A BR9910305 A BR 9910305A BR 9910305 A BR9910305 A BR 9910305A BR 9910305 A BR9910305 A BR 9910305A BR 9910305 A BR9910305 A BR 9910305A
Authority
BR
Brazil
Prior art keywords
agent
binding
vaccine
etxb
ctxb
Prior art date
Application number
BR9910305A
Other languages
Portuguese (pt)
Inventor
Timothy Raymond Hirst
Neil Andrew Williams
Andrew Morgan
Andrew Douglas Wilson
Lucy Amber Bird
Original Assignee
Univ Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9809958.3A external-priority patent/GB9809958D0/en
Priority claimed from GBGB9812316.9A external-priority patent/GB9812316D0/en
Application filed by Univ Bristol filed Critical Univ Bristol
Publication of BR9910305A publication Critical patent/BR9910305A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Resumo de Patente de Invenção para: <B>"VACINA"<D> Revela-se o uso de: (i) EtxB, CtxB ou VtxB livres da toxina completa; (ii) um agente diferente de EtxB ou CtxB, tendo atividade de ligação de GM1, ou um agente diferente de VtxB tendo atividade de ligação a Gb3; ou (iii) um agente tendo um efeito sobre os eventos de sinalização intracelular mediados por ligação a GM1 ou por ligação a Gb3; como um imunomodulador para uma vacina contra doenças infecciosas.Summary of Patent for: <B> "VACCINE" <D> The use of: (i) EtxB, CtxB or VtxB free of the complete toxin is disclosed; (ii) an agent other than EtxB or CtxB, having GM1 binding activity, or a different agent from VtxB having Gb3 binding activity; or (iii) an agent having an effect on intracellular signaling events mediated by binding to GM1 or binding to Gb3; as an immunomodulator for a vaccine against infectious diseases.

BR9910305A 1998-05-08 1999-05-10 Vaccine BR9910305A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9809958.3A GB9809958D0 (en) 1998-05-08 1998-05-08 Vaccine
GBGB9811954.8A GB9811954D0 (en) 1998-05-08 1998-06-03 Vaccine
GBGB9812316.9A GB9812316D0 (en) 1998-06-08 1998-06-08 Cancer vaccines
PCT/GB1999/001461 WO1999058145A2 (en) 1998-05-08 1999-05-10 Immunomodulators for vaccines

Publications (1)

Publication Number Publication Date
BR9910305A true BR9910305A (en) 2001-01-09

Family

ID=27269307

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910305A BR9910305A (en) 1998-05-08 1999-05-10 Vaccine

Country Status (18)

Country Link
EP (1) EP1075274A2 (en)
JP (1) JP4666761B2 (en)
KR (1) KR20070067719A (en)
CN (1) CN100335130C (en)
AU (1) AU3939499A (en)
BR (1) BR9910305A (en)
CA (1) CA2331832A1 (en)
CZ (1) CZ302333B6 (en)
EA (1) EA004794B1 (en)
GB (1) GB2353472A (en)
HU (1) HUP0104842A3 (en)
IL (1) IL139467A (en)
IS (1) IS5694A (en)
MX (1) MXPA00010934A (en)
NO (1) NO20005599L (en)
NZ (1) NZ507911A (en)
PL (1) PL344519A1 (en)
WO (1) WO1999058145A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20010036917A1 (en) 1995-07-05 2001-11-01 Williams Neil Andrew Therapeutic agents
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
KR20010043441A (en) 1998-05-08 2001-05-25 더 유니버시티 오브 브리스톨 Immunomodulators for vaccines
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB0030067D0 (en) * 2000-12-11 2001-01-24 Univ Bristol Therapeutic agent
GB0115382D0 (en) 2001-06-22 2001-08-15 Univ Bristol Mutant
CN111100824B (en) * 2020-01-21 2021-11-05 暨南大学 Bacillus and application thereof in denitrification and desulfurization in aquaculture water

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2004738A1 (en) * 1988-12-07 1990-06-07 University Of Leicester Heat-labile toxin b subunit fusion proteins
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
GB9513733D0 (en) * 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents
EP0919243A1 (en) * 1997-11-25 1999-06-02 Duphar International Research B.V Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
AU2232399A (en) * 1998-01-16 1999-08-02 Maxim Pharmaceuticals, Inc. Recombinant ctb-based vaccines

Also Published As

Publication number Publication date
EP1075274A2 (en) 2001-02-14
CZ20004147A3 (en) 2001-05-16
GB2353472A (en) 2001-02-28
GB0027072D0 (en) 2000-12-20
CN100335130C (en) 2007-09-05
EA004794B1 (en) 2004-08-26
WO1999058145A3 (en) 2000-02-03
MXPA00010934A (en) 2003-07-14
NO20005599L (en) 2001-01-08
NO20005599D0 (en) 2000-11-06
IL139467A0 (en) 2001-11-25
IS5694A (en) 2000-10-31
IL139467A (en) 2011-11-30
NZ507911A (en) 2004-04-30
JP2002514607A (en) 2002-05-21
PL344519A1 (en) 2001-11-05
HUP0104842A2 (en) 2002-04-29
EA200001134A1 (en) 2001-08-27
AU3939499A (en) 1999-11-29
KR20070067719A (en) 2007-06-28
CA2331832A1 (en) 1999-11-18
JP4666761B2 (en) 2011-04-06
HUP0104842A3 (en) 2002-12-28
CN1308546A (en) 2001-08-15
CZ302333B6 (en) 2011-03-16
WO1999058145A2 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
BRPI0111639B8 (en) use of an immunostimulatory oligodeoxynucleic acid molecule and pharmaceutical composition.
TR200101859T2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
MXPA02012712A (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity.
TR200002855T2 (en) Administration of raloxifene via the respiratory tract or nose.
ATE302606T1 (en) N-UREIDOALKYLPIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
ES2207298T3 (en) NEW ESTERS DERIVED FROM SUBSTITUTED FENIL-CICLOHEXIL COMPOUNDS.
CY1105120T1 (en) THE TREATMENT OF RESPIRATORY DISEASES
CL2004001129A1 (en) COMPOUNDS DERIVED FROM HALOGENOPIRIMIDINES ARIL TIO-ETER; PESTICIDE COMPOSITION; PREPARATION PROCEDURE; INTERMEDIARY COMPOUNDS; AND USE OF THE COMPOUND AS A PESTICIATED AGENT.
BR9908219A (en) Pro-perfumes cycles having release rates of alcohol raw material with modifiable fragrance
BR0110767A (en) Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
BR9910583A (en) Non-substituted aminotetralins as binders for the neuropeptide receptor y5 useful in the treatment of obesity and other disorders
DE69920757D1 (en) IMMUNE SUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES
BR9905110A (en) Combinations of active substances with insecticidal and acaricidal properties
BRPI0113162B8 (en) non-imidazole aryloxyalkylamine compounds and pharmaceutical composition comprising said compounds
BR9910305A (en) Vaccine
DK0998287T3 (en) Use of levobupivacaine
AR026968A1 (en) A MATRIX TABLET THAT ALLOWS THE PROLONGED TRIMETAZIDINE RELEASE AFTER YOUR ADMINISTRATION BY ORAL ROUTE
BR9916575A (en) Pharmaceutical composition of controlled release with tilidine mesylate as active substance
BR9910539A (en) Derivatives of 2 - (2 - chlorophenyl) - 3,4 - dihydro - 2h - pyrrole
DK1305037T3 (en) Painkiller
DE69819539D1 (en) ANTITHROMBOTIC AGENTS
ES2147453T3 (en) ADENOSINE ANTAGONISTS, PROCEDURE FOR ITS PREPARATION AND USE AS MEDICINES.
DK0750616T3 (en) Acid addition salts of 2,3,4,5-tetrahydro-1H-3-benzazapine compounds
BR0009194A (en) Composition of resorcinol
TR199901374T2 (en) Insecticidal and miticidal compositions

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]